Logo image of MMAT

META MATERIALS INC (MMAT) Stock Fundamental Analysis

USA - NASDAQ:MMAT - US59134N3026 - Common Stock

0.5258 USD
-0.11 (-17.84%)
Last: 8/20/2024, 8:00:00 PM
0.5013 USD
-0.02 (-4.66%)
After Hours: 8/20/2024, 8:00:00 PM
Fundamental Rating

2

Overall MMAT gets a fundamental rating of 2 out of 10. We evaluated MMAT against 112 industry peers in the Semiconductors & Semiconductor Equipment industry. MMAT may be in some trouble as it scores bad on both profitability and health. MMAT is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MMAT had negative earnings in the past year.
In the past year MMAT has reported a negative cash flow from operations.
MMAT had negative earnings in each of the past 5 years.
In the past 5 years MMAT always reported negative operating cash flow.
MMAT Yearly Net Income VS EBIT VS OCF VS FCFMMAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100M -200M -300M

1.2 Ratios

MMAT has a Return On Assets of -834.91%. This is amonst the worse of the industry: MMAT underperforms 99.08% of its industry peers.
MMAT's Return On Equity of -2111.11% is on the low side compared to the rest of the industry. MMAT is outperformed by 95.41% of its industry peers.
Industry RankSector Rank
ROA -834.91%
ROE -2111.11%
ROIC N/A
ROA(3y)-253.79%
ROA(5y)-164.97%
ROE(3y)-621.14%
ROE(5y)-405.97%
ROIC(3y)N/A
ROIC(5y)N/A
MMAT Yearly ROA, ROE, ROICMMAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K

1.3 Margins

MMAT's Gross Margin of 66.75% is amongst the best of the industry. MMAT outperforms 88.99% of its industry peers.
MMAT's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for MMAT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y183.27%
GM growth 5Y9.66%
MMAT Yearly Profit, Operating, Gross MarginsMMAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K

More info and screens

1

2. Health

2.1 Basic Checks

MMAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MMAT has been increased compared to 1 year ago.
The number of shares outstanding for MMAT has been increased compared to 5 years ago.
The debt/assets ratio for MMAT is higher compared to a year ago.
MMAT Yearly Shares OutstandingMMAT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M
MMAT Yearly Total Debt VS Total AssetsMMAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

MMAT has an Altman-Z score of -21.69. This is a bad value and indicates that MMAT is not financially healthy and even has some risk of bankruptcy.
MMAT's Altman-Z score of -21.69 is on the low side compared to the rest of the industry. MMAT is outperformed by 87.16% of its industry peers.
MMAT has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
MMAT's Debt to Equity ratio of 0.16 is in line compared to the rest of the industry. MMAT outperforms 48.62% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z -21.69
ROIC/WACCN/A
WACC8.82%
MMAT Yearly LT Debt VS Equity VS FCFMMAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

MMAT has a Current Ratio of 0.58. This is a bad value and indicates that MMAT is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.58, MMAT is doing worse than 94.50% of the companies in the same industry.
MMAT has a Quick Ratio of 0.58. This is a bad value and indicates that MMAT is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.57, MMAT is not doing good in the industry: 91.74% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.58
Quick Ratio 0.57
MMAT Yearly Current Assets VS Current LiabilitesMMAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

MMAT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.87%, which is quite impressive.
MMAT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.75%.
Measured over the past years, MMAT shows a very strong growth in Revenue. The Revenue has been growing by 44.10% on average per year.
EPS 1Y (TTM)36.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.6%
Revenue 1Y (TTM)13.75%
Revenue growth 3Y245.59%
Revenue growth 5Y44.1%
Sales Q2Q%131.54%

3.2 Future

MMAT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.10% yearly.
The Revenue is expected to grow by 175.50% on average over the next years. This is a very strong growth
EPS Next Y25.62%
EPS Next 2Y41.4%
EPS Next 3Y26.1%
EPS Next 5YN/A
Revenue Next Year312.22%
Revenue Next 2Y289.54%
Revenue Next 3Y175.51%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MMAT Yearly Revenue VS EstimatesMMAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
MMAT Yearly EPS VS EstimatesMMAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -5 -10 -15 -20 -25

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MMAT. In the last year negative earnings were reported.
Also next year MMAT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MMAT Price Earnings VS Forward Price EarningsMMAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MMAT Per share dataMMAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as MMAT's earnings are expected to grow with 26.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.4%
EPS Next 3Y26.1%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MMAT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

META MATERIALS INC

NASDAQ:MMAT (8/20/2024, 8:00:00 PM)

After market: 0.5013 -0.02 (-4.66%)

0.5258

-0.11 (-17.84%)

Chartmill FA Rating
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)03-28 2024-03-28/amc
Earnings (Next)N/A N/A
Inst Owners0.86%
Inst Owner Change0%
Ins Owners317.51%
Ins Owner Change0%
Market Cap3.33M
Analysts82.86
Price Target122.4 (23178.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)61.52%
Min EPS beat(2)42.65%
Max EPS beat(2)80.39%
EPS beat(4)4
Avg EPS beat(4)41.54%
Min EPS beat(4)21.57%
Max EPS beat(4)80.39%
EPS beat(8)5
Avg EPS beat(8)12.03%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-32.06%
Min Revenue beat(2)-46.31%
Max Revenue beat(2)-17.8%
Revenue beat(4)0
Avg Revenue beat(4)-24.91%
Min Revenue beat(4)-46.31%
Max Revenue beat(4)-13.72%
Revenue beat(8)1
Avg Revenue beat(8)-29.36%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.34
P/FCF N/A
P/OCF N/A
P/B 0.18
P/tB 2.38
EV/EBITDA N/A
EPS(TTM)-5.77
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-6.23
FCFYN/A
OCF(TTM)-5.15
OCFYN/A
SpS1.55
BVpS2.9
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -834.91%
ROE -2111.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.75%
FCFM N/A
ROA(3y)-253.79%
ROA(5y)-164.97%
ROE(3y)-621.14%
ROE(5y)-405.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y183.27%
GM growth 5Y9.66%
F-Score3
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.26%
Cap/Sales 69.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.58
Quick Ratio 0.57
Altman-Z -21.69
F-Score3
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)213.15%
Cap/Depr(5y)317.62%
Cap/Sales(3y)203.45%
Cap/Sales(5y)994.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.6%
EPS Next Y25.62%
EPS Next 2Y41.4%
EPS Next 3Y26.1%
EPS Next 5YN/A
Revenue 1Y (TTM)13.75%
Revenue growth 3Y245.59%
Revenue growth 5Y44.1%
Sales Q2Q%131.54%
Revenue Next Year312.22%
Revenue Next 2Y289.54%
Revenue Next 3Y175.51%
Revenue Next 5YN/A
EBIT growth 1Y47.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.72%
OCF growth 3YN/A
OCF growth 5YN/A